Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite posting strong quarterly results and outperforming major indices over the past year, U.S. Bancorp's stock is met with a measured 'Moderate Buy' consensus from analysts, highlighting a divergence between performance and sentiment.
Ark Invest's founder bolstered positions in key holdings across e-commerce, fintech, and cryptocurrency sectors ahead of major earnings reports, signaling confidence amidst market volatility.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of Coastal Financial (CCB) have retreated sharply from recent highs, reigniting the debate over the fintech-focused bank's premium valuation. While long-term performance remains strong, current momentum is fading, leaving investors to weigh high growth expectations against traditional valuation metrics.
Comcast announces a major restructuring of its connectivity division, appointing a new CEO, as it navigates a $240 million patent loss and gears up for a pivotal sports streaming season with the Olympics and Super Bowl on the horizon.
Shares of Philip Morris International have significantly outperformed the market over the past year, buoyed by its strategic shift towards reduced-risk products. While analysts remain broadly positive, recent downgrades signal growing caution about the pace of transformation and valuation.
Equinor's stock has gained ground over the past month, yet a detailed fair value analysis suggests the Norwegian energy giant may be trading at a premium. Investors are weighing strong long-term momentum against future headwinds from the green shift.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
Conagra Brands launches its protein-packed Banquet MEGA Breakfast Bowls, a direct challenge to rivals in the frozen aisle. While the move aligns with consumer trends, analysts question if it's enough to offset broader financial pressures facing the packaged food giant.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.
Citigroup initiates coverage of Dutch Bros Inc. with a Buy rating and an $82 price target, citing the drive-through coffee chain's successful national scaling and multiple drivers for sustained same-store sales growth over the coming years.
As the 2026 tax filing deadline approaches, new and expanded federal tax credits and deductions offer significant opportunities for filers to reduce their liability or increase their refund. Experts warn that millions overlook these benefits annually.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Despite posting blockbuster profits, Microsoft shares plunged 10% after its latest earnings, erasing hundreds of billions in market value. We examine whether Wall Street's reaction to cloud growth and AI spending fears is an overreaction or a prudent pause.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
As Bob Iger steps aside, incoming CEO Josh D'Amaro inherits a media giant facing stagnant growth, a challenged streaming division, and intense sector consolidation. Analysts debate whether a strategic overhaul or a potential sale offers the best path forward for the House of Mouse.
